Brief: Organogenesis Achieves Primary Endpoint In Phase 3 Clinical Trial Of Renu For Knee Osteoarthritis
02/05/2024 12:11
May 2 (Reuters) - Organogenesis Holdings Inc ORGO.O :
* ORGANOGENESIS ACHIEVES PRIMARY ENDPOINT IN PHASE 3
CLINICAL
TRIAL OF RENU® FOR KNEE OSTEOARTHRITIS
* ORGANOGENESIS HOLDINGS INC - STATISTICALLY SIGNIFICANT
(P<0.0001) MAINTENANCE OF FUNCTION AT SIX MONTHS
* ORGANOGENESIS HOLDINGS INC - STATISTICALLY SIGNIFICANT
(P=0.0177) REDUCTION IN KNEE PAIN AT SIX MONTHS
Source text for Eikon: ID:nGNX6jDw32
Further company coverage: ORGO.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Organogenesis Holdings
See all newsBrief: Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers